Negative
22Serious
Neutral
Optimistic
Positive
- Total News Sources
- 1
- Left
- 1
- Center
- 0
- Right
- 0
- Unrated
- 0
- Last Updated
- 1 day ago
- Bias Distribution
- 100% Left
NKGen Biotech, HekaBio Partner to Develop NK Cell Therapy in Japan
NKGen Biotech has entered a strategic collaboration with Tokyo-based HekaBio K.K. to develop, manufacture, and commercialize its autologous NK cell therapy, troculeucel, targeting neurodegenerative diseases such as Alzheimer's and Parkinson's in Japan. HekaBio will lead clinical trials and regulatory activities, leveraging Japan's expedited Regenerative Medicine guidelines to potentially begin patient dosing within the next year. The partnership aims to address significant health challenges posed by Japan's aging population and capitalize on faster market access provided by local regulations. Concurrently, NKGen secured $2 million in funding through a stock purchase agreement with HekaBio, which will support regulatory compliance efforts and the company's goal to uplist from the OTC Expert Market to higher exchanges like OTCQB, Nasdaq, or NYSE American. This funding also helps NKGen recover from challenges related to the bankruptcy of its former parent company, NKMax Co., Ltd., and to continue advancing its clinical trials and commercialization strategy in Japan. The collaboration underscores NKGen's commitment to bringing innovative cell therapies to markets with high unmet medical needs.

- Total News Sources
- 1
- Left
- 1
- Center
- 0
- Right
- 0
- Unrated
- 0
- Last Updated
- 1 day ago
- Bias Distribution
- 100% Left
Negative
22Serious
Neutral
Optimistic
Positive
Related Topics
Stay in the know
Get the latest news, exclusive insights, and curated content delivered straight to your inbox.

Gift Subscriptions
The perfect gift for understanding
news from all angles.